Executives from Heptares Therapeutics (Welwyn Garden City, UK) and o2h (Cambridge, UK) announced today an extension of the agreement under which o2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.
Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with o2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”
Sunil Shah, CEO, o2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”